miRNA-223在肝癌中的研究进展  

Research advance of miRNA-223 in hepatocellular carcinoma

作　　者：张蕾[1] 龚泽众 李岩[2] ZHANG Lei;GONG Zezhong;LI Yan(The Second Clinical College,Dalian Medical University,Dalian 116044,China;Department of Anatomy,Dalian Medical University,Dalian 116044,China)

机构地区：[1]大连医科大学第二临床学院,辽宁大连116044 [2]大连医科大学解剖教研室,辽宁大连116044

出　　处：《大连医科大学学报》2019年第3期272-276,共5页Journal of Dalian Medical University

摘　　要：内源性非编码小分子miRNA-223可作用于靶基因调控肝癌的发生发展,对肝癌细胞增殖、迁移、侵袭、凋亡以及耐药等生物学功能产生影响。血清与肿瘤中miRNA-223的表达水平对肝癌的诊断与治疗具有一定的参考价值,是肝癌诊断、治疗以及判断预后潜在的生物标志物。本文对近年来miRNA-223在肝癌中的研究进展作一综述。MiRNA-223 is a kind of endogenous small non-coding RNA,which has been shown to regulate the progression of hepatocellular carcinoma by targeting tumor suppressor or oncogenes. It plays a key role in cell proliferation,migration,invasion and drug resistance of hepatocellular carcinoma cell. The expression level of miRNA-223 in serum and liver tissues provides important reference value for the diagnosis and treatment of hepatocellular carcinoma,which makes miRNA-223 a potential biomarker for diagnosis,treatment and prognosis of hepatocellular carcinoma in clinic. We reviewed the research progress of microRNA223 in hepatocellular carcinoma in recent years.

关 键 词：肝癌 miRNA-223 IGF-IR STMN1 NLRP3 整合素αV亚基 

分 类 号：R735.7[医药卫生—肿瘤]